基于MRI筛选的低NIHSS评分急性缺血性卒中患者溶栓治疗研究
本研究回顾性分析2006年1月至2016年12月NIH卒中自然史数据库中121例初始NIHSS≤5分且经MRI筛选后4.5小时内接受溶栓的患者,评估症状性颅内出血和90天良好预后。结果显示症状性颅内出血率<1%,74%有90天数据的患者预后良好,在PRISMS合格亚组中无sICH发生且84%预后良好,提示MRI筛选下溶栓安全。
要点
- 初始NIHSS≤5分且经MRI筛选的患者溶栓后症状性颅内出血率<1%。
核心结论
- 经MRI筛选的低NIHSS评分急性缺血性卒中患者接受溶栓治疗是安全的。
- 未来针对该人群的研究可能受益于MRI筛选。
研究设计与样本
- 回顾性队列研究,审查NIH卒中自然史数据库2006年1月至2016年12月的数据。
- 纳入121例初始NIHSS≤5分且在症状发作4.5小时内接受溶栓前经MRI筛选的患者,中位年龄65岁,中位NIHSS 3分,63%为女性。
主要发现
- 任何出血转化率为13%,其中11%限于点状出血。
- 症状性颅内出血率<1%。
临床怎么用
- 对于初始NIHSS≤5分的急性缺血性卒中患者,可考虑在MRI筛选后4.5小时内进行溶栓治疗。
- MRI筛选可能有助于识别适合溶栓的低NIHSS评分患者。
局限性
- 本研究为回顾性研究,证据等级为Class IV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment of patients with stroke presenting with minor deficits remains controversial, and the recent Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) trial, which randomized patients to thrombolysis vs aspirin, did not show benefit. We studied the safety and efficacy of thrombolysis in a population of patients with acute stroke presenting with low NIH Stroke Scale (NIHSS) scores screened using MRI. METHODS: The NIH Natural History of Stroke database was reviewed from January 2006 to December 2016 to identify all patients with an initial NIHSS score ≤5 who received thrombolysis within 4.5 hours of symptom onset after being screened with MRI. The 24-hour postthrombolysis MRIs were reviewed for hemorrhagic transformation. Primary outcomes were symptomatic intracranial hemorrhage (sICH) and favorable 90-day outcome modified Rankin Scale score 0-1. Subgroup analysis was performed on patients who would have been eligible for the PRISMS trial, which enrolled patients with a nondisabling neurologic deficit. RESULTS: A total of 121 patients were included in the study with a median age of 65 and an NIHSS score of 3; 63% were women. The rate of any hemorrhagic transformation was 13%, with 11% of them being limited to petechial hemorrhage. The rate of sICH was <1%. Sixty-six patients had 90-day outcome data; of those, 74% had a favorable outcome. For the subgroup of 81 PRISMS-eligible patients, none experienced sICH. Fifty of these patients had 90-day outcome data; of these, 84% had a favorable outcome. CONCLUSIONS: Thrombolytic therapy was safe in our patients with stroke with minor deficits who were initially evaluated by MRI. Future studies of this population may benefit from MRI selection. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with acute ischemic stroke and NIHSS ≤5 screened with MRI, IV tissue plasminogen activator is safe.
引用
- Majidi S, Luby M, Lynch JK, et al. MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. Neurology. 2019. PMID: 31519779. doi:10.1212/WNL.0000000000008312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。